One of the world’s top twenty leading pharmaceutical groups, Boehringer Ingelheim, is entering the type 2 diabetes drug market. The company plans to develop diabetes drugs, revealing plans for a novel type of oral antidiabetic compound which have already reached phase 2/3 of clinical testing.
The firm has been on a period of expansion into new treatment areas, unveiling a cancer drug development programme just two years ago. The move into diabetes drug development will be conducted with ‘great pleasure’ according to the vice-chariman of the board responsible for running the company.
Dr. Andreas Barner reportedly commented: “Boehringer Ingelheim is scientifically, economically and intellectually well-prepared to successfully [broaden] its diabetes pipeline to meet the needs of physicians and their patients.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…